Dr Reddys Laboratories Ltd Share Price – NSE /  BSE

Pharmaceuticals, Mid Cap

Dr. Reddy's Laboratories announced the launch of its generic Semaglutide Injection in Canada. Dr. Reddy's is among the first companies to introduce a generic Semaglutide Injection in the Canadian market, following the Notice of Compliance (NOC) received from Health Canada on 28 April 2026. Canada is the first G7 country to grant market authorization for Semaglutide Injection. The launch demonstrates Dr. Reddy's readiness to ensure patient access following approval.

In Canada, Dr. Reddy's Semaglutide Injection is indicated for the once-weekly treatment of adults with type 2 diabetes mellitus, to improve glycemic control in combination with diet and exercise. It is supplied as a sterile solution for subcutaneous injection in a pre-filled pen, available in 2 mg/pen and 4 mg/pen strengths, each delivering Semaglutide at a concentration of 1.34 mg/ml. The 2 mg/pen is designed to deliver 0.25 mg or 0.5 mg doses, while the 4 mg/pen delivers 1 mg doses per injection.

Dr Reddys Laboratories Ltd fell for a fifth straight session today. The stock is quoting at Rs 1268.7, down 0.1% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.54% on the day, quoting at 23505.1. The Sensex is at 74897.31, up 0.45%.Dr Reddys Laboratories Ltd has gained around 4.18% in last one month.Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has increased around 6.93% in last one month and is currently quoting at 23840.9, up 0.63% on the day. The volume in the stock stood at 77.06 lakh shares today, compared to the daily average of 31.23 lakh shares in last one month.

The benchmark May futures contract for the stock is quoting at Rs 1269.7, up 0.13% on the day. Dr Reddys Laboratories Ltd jumped 3.99% in last one year as compared to a 4.71% slide in NIFTY and a 11.69% spurt in the Nifty Pharma index.

The PE of the stock is 22.85 based on TTM earnings ending December 25.

Powered by Capital Market - Live News

Securities in F&O Ban:

Steel Authority of India are banned from F&O trading on 13 May 2026.

Result Today:

Balaji Amines, The Bombay Burmah Trading Corporation, Bharti Airtel, Bharti Hexacom, CARE Ratings, Cipla, Crompton Greaves Consumer Electricals, DCM Shriram, DLF, eClerx Services, GlaxoSmithKline Pharmaceuticals, Hindustan Petroleum Corporation, Inventurus Knowledge Solutions, Interarch Building Solutions, JSW Dulux, Kaynes Technology India, Kirloskar Brothers, LIC Housing Finance, Man Infraconstruction, Metropolis Healthcare, NLC India, Oil Indi, Onesource Specialty Pharma, Paras Defence and Space Technologies, Power Finance Corporation, Quality Power Electrical Equipments, Redington, Sagar Cements, Sharda Cropchem, Signatureglobal (India), SKF India, Suven Life Sciences, Tourism Finance Corporation of India, Tube Investments of India, Tata Motors, TVS Holdings, TVS Motor Company, Zaggle Prepaid Ocean Services and ZF Commercial Vehicle Control Systems India

Stocks to Watch:

Dr. Reddy's Laboratories reported an 86.14% decline in consolidated net profit to Rs 220.9 crore on an 11.51% drop in revenue from operations to Rs 7,546.4 crore in Q4 FY26 compared with Q4 FY25.

Berger Paints India reported a 27.9% rise in consolidated net profit to Rs 335 crore from Rs 262 crore. Revenue increased 6.1% to Rs 2,868 crore from Rs 2,704 crore.

Dixon Technologies (India) reported a 35.91% decline in consolidated net profit to Rs 297.97 crore on a 2.12% increase in revenue from operations to Rs 10,510.51 crore in Q4 FY26 compared with Q4 FY25.

Neuland Laboratories reported a 665.1% jump in consolidated net profit to Rs 212.7 crore from Rs 27.8 crore. Revenue rose 134.8% to Rs 788.7 crore from Rs 335.8 crore.

Tata Power reported a 4.5% decline in consolidated net profit to Rs 996 crore from Rs 1,043 crore. Revenue fell 12.9% to Rs 14,900 crore from Rs 17,096 crore.

Torrent Power reported a 70% decline in consolidated net profit to Rs 318 crore from Rs 1,059 crore. Revenue slipped 0.8% to Rs 6,406 crore from Rs 6,456 crore.

Thomas Cook (India) reported a 40.1% decline in consolidated net profit to Rs 38.7 crore from Rs 64.6 crore. Revenue fell 10.1% to Rs 1,771 crore from Rs 1,969 crore.

Kalpataru reported a consolidated net profit of Rs 200 crore compared with Rs 14.1 crore a year ago. Revenue surged 183.7% to Rs 1,694 crore from Rs 597 crore.

Powered by Capital Market - Live News

Dr Reddys Laboratories has fixed 10 July 2026 as record date for payment of final dividend of Rs 8 per equity share of Re 1 for FY 2025-26.